Kornimate/medical-research-clean huggingface dataset:
people living with hiv/aids, nitrate, endotelial function, arterial stiffness and skeletal muscle oxygenation

Conditions: HIV/AIDS

Summary: administration of antiretroviral therapy has brought benefits for infective human immunodeficiency virus-1 (hiv-1)-patients, reducing the number of aids-related morbidity and mortality. however, it is responsible for intensifying complications triggered by the chronic inflammatory state associated with virus infection, such as cardiovascular diseases. the current study evaluated effects of single dose (140ml) of beetroot juice (bj) on macro and microvascular endothelial function in hiv-1-patients undergoing antiretroviral terapy, once bj was shown to be effective in improving these physiological parameters in uninfected individuals.


Eligibility criteria:
inclusion criteria: * hiv infection for a period of 1 year or greater * regular use of high-potency antiretroviral therapy for at least one year exclusion criteria: * individuals who are physically active * individuals who are allergic to some component of beet * individuals who use nutritional and / or pharmacological ergogenics * individuals receiving antibiotics or who have osteomioarticular problems

Keywords: hiv/aids arterial stiffness flow mediated-dilatation muscle oxygenation parameters microcirculation dietary nitrate
diagnosing minimal hepatic encephalopathy

Conditions: Hepatic Encephalopathy; Liver Cirrhosis

Summary: our purpose is to 1. examine the correlation between mdf in a resting eeg, recorded just before the crt test, and the variance in reaction times indicated by the crt index 2. at simultaneous crt and eeg recording, examine whether a change in eeg is seen immediately before an extended reaction time occurs (defined by the 75th percentile). this will shed light on a direct pathophysiological association between what is measured with eeg and crt. 3. investigate whether cyclicity can be detected in the continuous reaction times and if so, whether amplitude and wavelength in this cyclic activity are correlated to eeg parameters. 4. examine whether a response to standard he treatment can be detected with eeg in patients who are thought to suffer from it. as well as if baseline outcome predict future hepatic encephalopathy. 5. with a view to further validating our findings, investigators want to correlate results from eeg and crt with the most internationally widespread psychometric test, the portosystemic encephalopathy test (pse), which necessitates the establishment of danish normal values. a secondary purpose of this study is therefore 6. to establish danish normal values for the pse test and the animal naming test in danes


Eligibility criteria:
inclusion criteria for patients with liver cirrhosis: 1. age\> 18 2. liver cirrhosis verified by biopsy or appropriate clinic and biochemistry as well as imaging. 3. written informed consent 4. speaks and understands danish for the subgroup with liver cirrhosis and normal cognition: 1. normal result in pse and crt testing and clinical examination without evidence of he for the subgroup with liver cirrhosis and minimal hepatic encephalopathy: 2. abnormal result in pse and / or crt test, but oriented in time, place and own data. for the subgroup with liver cirrhosis and he grade 2, the following applies: 3. abnormal pse and crt result and / or disoriented in time, place or own data and / or asterixis or other clinical symptoms of he 4. ability to collaborate on the performance of crt test, pse test and eeg inclusion criteria healthy: 1. liver healthy 2. age over 18 years 3. formal education ≤ 14 years 4. written informed consent 5. speaks and understands danish inclusion criteria for pre-cirrhosis liver disease: as for healthy controls plus: 1. in our local outpatient clinic 2. proven pre-cirrhosis liver disease exclusion criteria: 1. organic brain disease (eg previous epilepsy, apoplexy, dementia) 2. hyponatraemia (na \<124 mmol / l) 3. sepsis one week prior to tests. 4. heart failure (ec less than 30% or nyha class iii and iv) 5. severe chronic obstructive pulmonary disease (gold stage 3 and 4 ie fev1 / fvc below 0.7 and fev1 \<50% of expected value) 6. highly controllable diabetes (hba1c\> 60 mmol / mol) 7. renal failure (egfr below 60) 8. known neurological diseases (epilepsy, stroke, dementia) 9. intake of coffee or alcohol 6 hours before tests and change of dose in psychoactive drugs within 6 days of the test (morphine, antipsychotics, antidepressants) -
a plant based high protein diet to improve nutritional outcomes in peritoneal dialysis patients

Conditions: End-Stage Renal Disease; Malnutrition

Summary: the study proposes that addition of high protein plant based diet will improve serum albumin as well serum phosphate for patients with end stage renal disease (esrd) on dialysis. patient will be provided additional food items to help improve their nutritional status.

the purpose of this study is to improve the albumin and nutritional status of patient with esrd on dialysis. serum albumin is a marker to show how well the patient's overall nutrition is. when albumin level drops it signifies poor outcome in dialysis patients both in terms of complications as well as mortality. our goal on dialysis is to improve serum albumin level as close to normal as possible. this study intends to also improve phosphorus level by adding high protein sources which are plant based. in this study we intend to add certain plant based food items which are high in protein content. studies have shown that these particular food items considerably increase serum albumin level but at the same time they are safe as they do not increase the phosphorous levels in kidney patients. patients will be provided the additional food items and all their nutritional parameters will be monitored at baseline and during the study period of one month

Eligibility criteria:
inclusion criteria: * esrd patients on dialysis with an albumin of \<4.0 with the ability to consent and willingness to enroll in the study exclusion criteria: * other exclusions include * liver cirrhosis, * cardiac cirrhosis, * dysphagia due to an old cerebrovascular accident / muscular dystrophy, * hyperkalemia (\>5.5)
home based hip strengthening for knee oa patients

Conditions: Knee Osteoarthritis

Summary: in knee osteoarthritis patients, weakness of hip abductor muscles is considered an important contributing factor leading to the progression of the disease.

osteoarthritis is the most common type of disease that results from an abnormality in joint function. osteoarthritis(oa) is a condition that is characterized by progressive loss of articular cartilage of a joint and causes pain. yamda et al. found that the strength of hip adductors increases with the severity of the disease. this reflects that more use of these muscles lower knee adductor moment 54. considering this research, knee loads can be altered by strengthening hip muscles. pakistan is listed in 3rd world countries and the poverty index is high. many patients show reluctance in going to clinics for the physiotherapeutic management of knee oa. so, the present research intends to investigate the effects of home-based hip strengthening exercise on pain, functions, and range of motion in elderly knee osteoarthritis patients.

Eligibility criteria:
inclusion criteria: * the age group was from 40 to 60 years. * both males and females were included. * average knee pain on walking \>3 on an 11-point scale (nprs) (0 no pain; 10 maximal pain). * participants can walk independently without any assistive devices * diagnosed patients of grade ii \& iii of kallgren and lawrence scale for knee osteoarthritis referred by an orthopaedic surgeon exclusion criteria: * history of osteoporosis. * leg length discrepancy or structural deformity * knee surgery or tkr. * corticosteroid injection in knee joint * systemic arthritic condition * history of tibiofemoral and patellofemoral replacement * any other neurological and muscular condition affecting the lower limb * any history of radiculopathy.

Keywords: osteoarthritis home-based exercise plan functional disability obesity
using personalized assessments in the treatment of childhood ocd

Conditions: Obsessive-Compulsive Disorder

Summary: the primary purpose of this study is to learn whether personalized assessment of obsessive-compulsive disorder (ocd) symptoms in childhood ocd using mobile health technology are feasible and acceptable for youth and parents. the investigators will also examine whether personalized cognitive-behavioral therapy (cbt) that is informed by personalized ocd assessments yields better clinical outcomes when compared to standard cbt for youth with ocd


Eligibility criteria:
inclusion criteria: 1. be 8-17 years of age; 2. meet diagnostic criteria for a primary diagnosis of ocd on a structured clinical interview; 3. have moderate ocd severity as evidenced by a cy-bocs total score of ≥16; 4. medication free and/or on a stable dose of medication 8 weeks prior to study participation; 5. be english speaking. exclusion criteria: 1. the presence of psychotic disorder, bipolar disorder, or autism spectrum disorders; 2. significant suicidal ideation that warrants medical intervention; 3. concurrent psychotherapy for ocd; 4. inability to complete scales, or attend visits.

Keywords: children adolescents exposure with response prevention cognitive behavioral therapy erp cbt
sweet taste responsiveness in relation to insulin, leptin and adiposity among obese treatment seeking children

Conditions: Pediatric Obesity

Summary: this study will explore whether a relationship exists between insulin and leptin resistance, sweet taste responsiveness, and adiposity.

compared to healthy weight peers, some reports have shown that they are less sensitive to, or perceptive of, sucrose solutions and sweet foods, whereas others have observed the opposite pattern of findings or no difference at all. among those seeking weight loss treatment, one investigation found perception and preferences for sweet taste remained unchanged after weight loss, and another observed a decreased ability to distinguish sweet taste from other taste solutions. given these discrepancies in the literature, the proposed study will explore whether a relationship exists between insulin and leptin resistance, sweet taste responsiveness, and adiposity.

Eligibility criteria:
inclusion criteria: * patient of children's healthy weigh of buffalo * ages of 8-14 if enrolled in the bariatric arm: • must be scheduled for bariatric surgery prior to enrollment exclusion criteria: * patients unable to get labs drawn at a kaleida facility * severe hay fever or seasonal allergies within 2 weeks of enrollment * smoker or are exposed to second-hand smoke at home, * has been dieting to lose weight within the past 6 months of enrollment * currently taking any prescription medications that can influence taste or small functions or are pregnant. * pregnancy * bariatric arm patients will be excluded if they fail to have the surgery.

Keywords: leptin insulin sweet responsiveness weight loss
impact of naloxone on the analgesic effect of paracetamol in healthy volunteers

Conditions: Pain

Summary: the aim of this study is to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials.

double blind, cross-over study in healthy volunteers.

Eligibility criteria:
inclusion criteria: * healthy men * between 18 and 40 years old * written consent given exclusion criteria: * naloxone or paracetamol hypersensibility * excessive consumption of alcohol, tobacco, coffee, tea or toxicomania * concomitant medication

Keywords: pain, sensitization, analgesia
cobimetinib for braf-wild-type or mutated histiocytoses

Conditions: Disease or R Group Histiocytoses

Summary: cobrah is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel groups. patients will be randomly assigned in a 2:1 ratio to receive cobimetinib orally or placebo during the first 12-weeks step, allowing the determination of the primary criteria.

histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. virtually all the patients have a somatic mutation in the ras-raf-mek-erk pathway. braf inhibitors are efficacious to treat braf-mutated patients but one third of the patients are braf-wild type. for these patients, preliminary data have shown an efficacy of the mek inhibitor cobimetinib. this trial aims to evaluate the efficacy of cobimetinib for treating braf-wild type or mutated patients with l or r group histiocytoses. the primary objective of the cobrah trial is to demonstrate that the rate of objective metabolic response (complete or partial) according to percist criteria is higher under cobimetinib versus placebo. the objective metabolic response according to percist criteria (haroche, et al. 2015) is defined by the positron emission tomography (pet) response and will be used to evaluate the overall therapeutic response at month 3 (week 12). for percist criteria, a quantitative analysis of uptake will be performed using the standard uptake value (suv). fitting regions of interest covering pathologic uptake will be used to define target lesions. percist will be used to classify the patients as complete metabolic response, partial metabolic response (reduction of a minimum of 30% in target lesions), stable metabolic disease or progressive metabolic disease.

Eligibility criteria:
inclusion criteria: * eligible patients should be at least 18 years of age, * have a histologically confirmed l or r group histiocytoses without brafv600e mutation detected with the use of a real-time polymerase chain reaction or with brafv600e mutation and a contra-indication to braf inhibitors * have a measurable disease according to the percist criteria with presence of at least one severe organ involvement (heart, vascular, central nervous system) or a multisystemic disease with ≥3 organ involvement and failure of a first-line treatment or contra-indication to these treatments, * accepting effective contraception during treatment duration (men and women childbearing potential) and 3 months after. * signed informed consent exclusion criteria: * patients with severe hepatic, renal and cardiac outcomes * patients with myopathies at baseline * patients with retinal detachment at baseline * patients with inherited disorders of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption * patients with high bleeding risk. * allergies to iodized contrast media * simultaneous participation in another medical research * pregnancy or breast-feeding. * no affiliation to the french health care system "sécurité sociale" or no affiliation of european health within the scope of regulations (eec) n° 1408/71 and 574/72 coordinating social security systems.
study of proteins in head and neck cancer cells

Conditions: Head and Neck Cancer

Summary: rationale: studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is looking at proteins in head and neck cancer cells.

objectives: * define the function and mechanism of lzap in regulating arf. * determine the mechanism and biological consequences of lzap inhibition of nf-κb. * determine if lzap has tumor suppressor activity by conditional targeting of lzap in mice. outline: using molecular laboratory techniques, this study examines the biochemical mechanisms by which lzap activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of arf and inhibits transcriptional, tumorigenic activity of nf-kb. lzap regulation of newly identified arf activities, such as s-phase delay and arf-mediated b23 degradation are also evaluated. lzap's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target lzap in mice and to observe for spontaneous and induced tumor formation. laboratory analyses used to determine study endpoints include standard recombinant dna, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, tunel assay, elisa assay, southern blotting, and protein and gene expression.

Eligibility criteria:
disease characteristics: * head and neck cancer tumor cell line patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: head and neck cancer
effect of hydrotherapy on multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this work was to investigate the effect of a hydrotherapy program on the balance and fatigue of patients with multiple sclerosis. it is a fact that hydrotherapy has an effect on the rehabilitation and treatment of people with balance problems.

26 patients with multiple sclerosis participated in the present research, who were divided into 2 intervention groups, one in the sea and one on land. the intervention program had a duration of 2 months with a frequency of 2 times a week for both groups. the interventions were performed by specialized therapists. all participants were assessed before and after the intervention using the bbs and mfis scales.

Eligibility criteria:
inclusion criteria: * diagnosed with rr-type (relapsing-remitting) multiple sclerosis by ms ( multiple sclerosis) expert neurologists, and expanded disability status scale (edss) cit 10 score of 1-3.7 participated in this study. exclusion criteria: * older than 45 years; edss score\>3,7; primary progressive ms; acute or chronic physical or psychological disorders; participation in less than 12 of the 16 hydrotherapy sessions; common contraindications for hydrotherapy as cardiovascular disease, allergy etc.,
changes of immunologic function in patients of prostate cancer induced after cryoablation.

Conditions: Prostate Cancer

Summary: 1. the overall objective of the study: by evaluating the curative effect of csap in localized prostate cancer, locally advanced prostate cancer and metastasis advanced prostate cancer, and the change of state in cellular immunity and humoral immunity before and after csap. validate the clinical therapeutic effect of all kinds of prostate cancer, as well as the change of immune status before and after csap. 2. the main content of the study: 1. included in the samples are patients in hospitals for csap. the sample capacity are planned to be 80. the main purpose of the study is to observe the overall survival rate , disease free survival rate, the progress time of the psa biochemical recurrence as well as the disease progress time. 2. measure the change of concentration in peripheral blood t lymphocyte subsets (cd3 + t, cd4 + t, cd8 + t, cd4 + / cd8 + t, nk cells) and regulatory t cells before and after cryoablation within 1 month, 3 months and 6 months. 3. measure the change of concentration in peripheral blood ifn-1, il-4, ifn-1/il-4 ratio (thl/th2 ratio), and detect the secretion of cd4 + th tumor-specific ifn-l and the activity of tumor-specific killer cd8 + ctl before and after cryoablation within 2 weeks and 1 month. 4. before cryoablation, detect the expression and distribution of follistatin-like1 (fstl-1), besides, verify the connection between the number and activation ratio of tumor local dendritic cells (dc) and the fstl-1, evaluating the cryoablation effect on the immune response.


Eligibility criteria:
inclusion criteria: * patients diagnosed with prostate cancer by pathology * the age of patients should be from 40 to 80 years old * do not receive other treatments like radical prostatectomy, radiotherapy, etc exclusion criteria: * can not receive surgery because of bad performance status * abnormal coagulation function * receive other treatment before csap * do not want to achieve csap because of any reasons
transcranial direct current stimulation (tdcs) combined with computerized cognitive addiction therapy(ccat) and, electronic follow-up for methamphetamine(ma) dependent patients

Conditions: Methamphetamine-dependence; Transcranial Direct Current Stimulation; Computerized Cognitive AddictionTherapy; Electronic Health Records

Summary: transcranial direct current stimulation (tdcs) combined with computerized cognitive addiction therapy(ccat) for methamphetamine(ma) dependent patients in voluntary drug rehabilitation center. electronic medical systems were applied for drug related knowledge education, self-evaluation and outpatient follow-up reminder after intervention in order to reduce relapse behaviors.


Eligibility criteria:
inclusion criteria: * methamphetamine dependent patients with normal eyesight and hearing. exclusion criteria: * any diagnosis of dsm-iv axis i diseases. * any physical diseases which might influence cognitive function such as epilepsy, cerebrovascular disease or brain injury. * negative behaviors or harm to others. * cognitive enhance drug use history in last 6 months. * other drug dependence(except nicotine).
safety and efficacy study of cefepime/vnrx-5133 in patients with complicated urinary tract infections

Conditions: Urinary Tract Infections; Acute Pyelonephritis

Summary: this study will assess the safety and efficacy of cefepime/vnrx-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cutis.


Eligibility criteria:
inclusion criteria: * adult male and female * documented diagnosis of pyuria * documented diagnosis of cuti or acute pyelonephritis (ap) exclusion criteria: * receipt of effective antibacterial drug therapy for cuti for more than 24 hours during the previous 72 hours prior to randomization * a urine culture result is resistant to meropenem or a gram negative pathogen is not identified or more than 2 microorganisms are isolated or a confirmed fungal uti is identified * required use of nonstudy systemic bacterial therapy * suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually transmitted disease * patients with perinephric or renal abscess * patients with renal transplantation or receiving hemodialysis or peritoneal dialysis * abnormal labs

Keywords: bacterial infections cefepime meropenem complicated urinary tract infections anti-infective agents β-lactamase inhibitors vnrx-5133 (taniborbactam)